Actinic keratosis
Guideline highlights
Although they often persist as chronic skin lesions, AKs can spontaneously involute, or most importantly, evolve into keratinocyte carcinoma if left untreated.
Treatment options for AK include field-directed therapies, such as topical medications and photodynamic therapy, and lesion-directed therapies, like cryosurgery and laser ablation.
Analysis of the evidence from a systematic review based on five research questions resulted in eighteen evidence-based recommendations and suggests there are several effective treatments available for AK.
Strong recommendations were made for the use of UV protection, cryosurgery, topical imiquimod, and 5-FU. Conditional recommendations were made for the use of PDT and diclofenac for the treatment of AK, both individually and as part of combination therapy regimens.
In a focused update published in June 2022, a strong recommendation for the use of tirbanibulin as field therapy was added to the guidelines.
Full AK guideline in JAAD
Go to the actinic keratosis guidelineYou can also access a focused update on tirbanibulin to the AK guideline in JAAD.
View the Academy guidelines disclaimer.
Are you a patient with actinic keratosis?
See our AAD actinic keratosis pages for information on how to treat and manage your AK.
Find a Dermatologist
Member directory
AAD Learning Center
2026 AAD Innovation Academy
Need coding help?
Reduce burdens
Clinical guidelines
Why use AAD measures?
New insights
Physician wellness
Joining or selling a practice?
Promote the specialty
Advocacy priorities